|
Marty...I just finished reading the company prospectus and am impressed with the possible risk/reward possiblities...My only hesitation is the lack of valuation( read: interest) that Wall Street currently places on gene therapy companies...Looking at companies as CEGE, GMED, SOMA, VICL, ARIA, etc., there is little "inflation" in their valuation...In fact, you could own this entire crew for $500 million or less...HOWEVER, if I back up a year or two ago and look at some of the genomic companies, e.g., INCY, HGSI, etc., they were trading in the teens and certainly have made some impresssive gains...Incyte has gone from $15 to $68...I am hesitant to have money "sitting", waiting to be "appreciated"...I am a believer that at some time the bell will ring for these equities, I am just not sure this is their year...Thoughts?.. |
